Ann Dermatol.  2016 Aug;28(4):522-523. 10.5021/ad.2016.28.4.522.

Palmoplantar Pustulosis Induced by both Adalimumab and Golimumab for Treatment of Ankylosing Spondylitis

• Seol JE
• Park IH
• Lee W
• Kim H
• Jung SY
• Wang HY

• KMID: 2344835
• DOI: http://doi.org/10.5021/ad.2016.28.4.522

Abstract

No abstract available.

MeSH Terms

Adalimumab*
Spondylitis, Ankylosing*
Adalimumab

Figure

• 

  Fig. 1 Erythematous scaly patch with pustules on both palms were seen.

• 

  Fig. 2 (A) Histopathologic findings of the lesion showed psoriasiform epidermal hyperplasia with perivascular inflammatory cell infiltration in the papillary dermis (H&E, ×40). (B) Parakeratosis and intraepidermal spongiform bullae filled with neutrophils was observed in expanded view (H&E, ×200).

Reference

1. Wendling D, Prati C. Paradoxical effects of anti-TNF-α agents in inflammatory diseases. Expert Rev Clin Immunol. 2014; 10:159–169.

2. Smolen JS, Kay J, Doyle MK, Landewé RB, Matteson EL, Gaylis N, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomized, double-blind, placebo-controlled, phase III trial. Lancet. 2009; 374:210–221.

3. Collamer AN, Guerrero KT, Henning JS, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum. 2008; 59:996–1001.

4. Ko JM, Gottlieb AB, Kerbleski JF. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J Dermatolog Treat. 2009; 20:100–108.

5. Nguyen K, Vleugels RA, Velez NF, Merola JF, Qureshi AA. Psoriasiform reactions to anti-tumor necrosis factor α therapy. J Clin Rheumatol. 2013; 19:377–381.